Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
Luise Rogg, Sebastian A Nuñez, María Verónica Mingrone et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled phase 2a trial assessed short-course oral VH-184 monotherapy in adults with HIV-1 who were antiretroviral-therapy naive and had HIV-1 RNA ≥ 3000 copies/mL. Participants received one of three VH-184 doses or placebo on days 1, 4, and 7, then began standard-of-care ART on day 10. Mean maximum HIV-1 RNA changes through day 10 were -1.17, -2.15, and -2.31 log10 copies/mL with 10, 50, and 300 mg, respectively. No treatment-emergent resistance was detected, and no serious safety signal was reported.
Key findings
- Mean maximum HIV-1 RNA change through day 10 was -1.17, -2.15, and -2.31 log10 copies/mL with VH-184 10, 50, and 300 mg, respectively.
- No VH-184 genotypic or phenotypic resistance was detected through day 10.
- No adverse events leading to withdrawal, treatment-emergent serious adverse events, or deaths occurred.
Why it matters
The findings provide early clinical evidence that VH-184 has antiviral activity across the tested doses, alongside short-term tolerability and no detected resistance during the study period. These results are relevant to development of integrase inhibitors intended for HIV-1 treatment, but the brief monotherapy evaluation does not establish effectiveness or safety as part of a complete, longer-term regimen.
What to keep in mind
The trial was small (22 participants), evaluated monotherapy for only a short period, and participants began standard-of-care ART on day 10; longer-term efficacy, safety, and resistance outcomes are not established.